Please login to the form below

Not currently logged in
Email:
Password:

MEDI4736

This page shows the latest MEDI4736 news and features for those working in and with pharma, biotech and healthcare.

AZ gets orphan status for selumetinib in thyroid cancer

AZ gets orphan status for selumetinib in thyroid cancer

immuno-oncology candidate durvalumab (MEDI4736).

Latest news

More from news
Approximately 6 fully matching, plus 28 partially matching documents found.

Latest Intelligence

  • Pharma deals in August 2015 Pharma deals in August 2015

    AstraZeneca will collaborate with Peregrine on a non-exclusive basis looking at the combination of bavituximab and durvalumab [MEDI4736] in solid tumours.

  • Pharma deals in April 2015 Pharma deals in April 2015

    Completing the deal haul is the exclusive collaboration around AZ's MEDI4736 for an upfront payment of $450m plus royalties. ... MEDI4736 is an immune checkpoint inhibitor which is targeted against programmed cell death (PD-L1).

  • Medius Deal Watch table for April 2015 Medius Deal Watch table for April 2015

    485. AstraZeneca/Celgene. Exclusive collaboration. MEDI4736 - an investigational checkpoint inhibitor in serious blood cancers.

  • Pharma deals during November 2014 Pharma deals during November 2014

    AZ has been busy this month and in the deal with J&J, AZ will match its closely-watched PD-L1 checkpoint inhibitor MEDI4736 with Imbruvica. ... MEDI4736 blocks the signals that help tumours avoid detection by the immune system, countering the tumour's

  • Pharma deals during July 2014 Pharma deals during July 2014

    The focus of the study will be KHK's anti-CCR4 antibody, mogamulizumab, in combination with either AZ's anti-PD-L1 antibody, MEDI4736, or AZ's anti-CTLA-4 antibody

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anatomy Health

We are a health information design consultancy focused on developing simple, accessible and inclusive patient communications. From evaluating existing patient...

Latest intelligence

Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...
Light_bulb_Stock_Market.jpg
Creativity has lost its worth
Creativity has lost its worth, and sadly it is undermining effectiveness...

Infographics